Proteomics in Clinical Trials and Practice

The study of clinical proteomics is a promising new field that has the potential to have many applications, including the identification of biomarkers and monitoring of disease, especially in the field of oncology. Expression proteomics evaluates the cellular production of proteins encoded by a particular gene and exploits the differential expression and post-translational modifications of proteins between healthy and diseased states. These biomarkers may be applied towards early diagnosis, prognosis, and prediction of response to therapy. Functional proteomics seeks to decipher protein-protein interactions and biochemical pathways involved in disease biology and targeted by newer molecular therapeutics. Advanced spectrometry technologies and new protein array formats have improved these analyses and are now being applied prospectively in clinical trials. Further advancement of proteomics technology could usher in an era of personalized molecular medicine, where diseases are diagnosed at earlier stages and where therapies are more effective because they are tailored to the protein expression of a patient’s malignancy.

[1]  E. Kohn,et al.  Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Maode Lai,et al.  Identification of differentially expressed proteins in colorectal cancer by proteomics: Down‐regulation of secretagogin , 2006, Proteomics.

[3]  Marie-Christine W. Gast,et al.  Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. , 2006, Trends in pharmacological sciences.

[4]  R. Aebersold,et al.  Mass Spectrometry and Protein Analysis , 2006, Science.

[5]  W. Gradishar,et al.  Gene expression in breast cancer , 2006, Current treatment options in oncology.

[6]  T. Beach,et al.  Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.

[7]  A. Zlotta.  Auto-Antibody Signatures in Prostate Cancer , 2006 .

[8]  E. Ariazi,et al.  Estrogen receptors as therapeutic targets in breast cancer. , 2006, Current topics in medicinal chemistry.

[9]  F. Luo,et al.  Hypoxia-inducible transcription factor-1α promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway , 2006, BMC Cancer.

[10]  M. Cronin,et al.  Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes , 2005, Clinical Cancer Research.

[11]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[12]  Daohai Zhang,et al.  Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer* , 2005, Molecular & Cellular Proteomics.

[13]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[14]  Ø. Bruserud,et al.  Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. , 2005, Current drug targets.

[15]  A. Alaiya,et al.  Clinical cancer proteomics: promises and pitfalls. , 2005, Journal of proteome research.

[16]  Walter Kolch,et al.  The molecular make-up of a tumour: proteomics in cancer research. , 2005, Clinical science.

[17]  P. Speckman,et al.  Proteomic analysis of nipple aspirate fluid using SELDI‐TOF‐MS , 2005, International journal of cancer.

[18]  Brian L Hood,et al.  Biomarkers: Mining the Biofluid Proteome* , 2005, Molecular & Cellular Proteomics.

[19]  E. Kohn,et al.  Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. , 2005, Clinical colorectal cancer.

[20]  Yue Hu,et al.  [Diagnostic application of serum protein pattern and artificial neural network software in breast cancer]. , 2005, Ai zheng = Aizheng = Chinese journal of cancer.

[21]  Serge Batalov,et al.  The promise of genomics to identify novel therapeutic targets , 2004, Expert opinion on therapeutic targets.

[22]  M. Cotten,et al.  Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors* , 2004, Molecular & Cellular Proteomics.

[23]  S. Haggarty,et al.  Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Stephen Alexander,et al.  Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid , 2004, Clinical Cancer Research.

[25]  I. Gromova,et al.  Impact of proteomics on bladder cancer research. , 2004, Pharmacogenomics.

[26]  E. Petricoin,et al.  Biomarkers of ovarian tumours. , 2004, European journal of cancer.

[27]  Laura Beretta,et al.  Proteomics for hepatocellular carcinoma marker discovery. , 2004, Gastroenterology.

[28]  L. Stein.  21.10 n&v 915 MH , 2004 .

[29]  Lisa H. Cazares,et al.  Surfaced-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) Differentiation of Serum Protein Profiles of BRCA-1 and Sporadic Breast Cancer , 2004, Annals of Surgical Oncology.

[30]  M. Gleave,et al.  Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis , 2004, Cancer Research.

[31]  Masaaki Ito,et al.  Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer , 2004, Clinical Cancer Research.

[32]  Qing‐Yu He,et al.  Application of Proteomics in the Study of Tumor Metastasis , 2004, Genomics, proteomics & bioinformatics.

[33]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[34]  S. Steinberg,et al.  A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Petricoin,et al.  Clinical proteomics: Applications for prostate cancer biomarker discovery and detection. , 2004, Urologic oncology.

[36]  A. Verma,et al.  Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells* , 2004, Journal of Biological Chemistry.

[37]  D. Brehmer,et al.  Proteome-wide Identification of Cellular Targets Affected by Bisindolylmaleimide-type Protein Kinase C Inhibitors* , 2004, Molecular & Cellular Proteomics.

[38]  T. Isono,et al.  Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. , 2004, Clinical chemistry.

[39]  Rembert Pieper,et al.  Characterization of the human urinary proteome: A method for high‐resolution display of urinary proteins on two‐dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots , 2004, Proteomics.

[40]  K. Sandelin,et al.  Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment , 2004, Molecular & Cellular Proteomics.

[41]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[42]  Kelly K. Hunt,et al.  Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry , 2004, Breast Cancer Research and Treatment.

[43]  O. John Semmes,et al.  SELDI-TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast Cancers , 2004, Disease markers.

[44]  M. Cotten,et al.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Atlas,et al.  Magnetic resonance image–guided proteomics of human glioblastoma multiforme , 2003, Journal of magnetic resonance imaging : JMRI.

[46]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[48]  Rob Pieters,et al.  Identification of Tumor‐Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors , 2003, Journal of neuropathology and experimental neurology.

[49]  S. Gygi,et al.  Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry , 2003 .

[50]  J. Roboz,et al.  Putative protein markers in the sera of men with prostatic neoplasms , 2003, BJU international.

[51]  M. Kostrzewa,et al.  Mass spectrometry-based clinical proteomics. , 2003, Pharmacogenomics.

[52]  K. Lindpaintner,et al.  Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia , 2003, Amino Acids.

[53]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[54]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[55]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[56]  C. Verschraegen,et al.  Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. , 2002, Anticancer research.

[57]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[58]  L. Liotta,et al.  Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer , 2002, Disease markers.

[59]  S. Schnitt.  Traditional and newer pathologic factors. , 2001, Journal of the National Cancer Institute. Monographs.

[60]  E. Petricoin,et al.  Clinical proteomics: personalized molecular medicine. , 2001, JAMA.

[61]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[62]  Jean-Charles Sanchez,et al.  Proteomics: new perspectives, new biomedical opportunities , 2000, The Lancet.

[63]  W. Donegan.  Tumor‐related prognostic factors for breast cancer , 1997, CA: a cancer journal for clinicians.

[64]  G. Murphy,et al.  Prostate antigen: a marker for human prostate epithelial cells. , 1981, Journal of the National Cancer Institute.